BiotechFrance

To finance the research programs of its vaccine candidates in asthma and food allergy, the company founded in 1993 has raised nearly €40M in the form of convertible bonds (Oceane) since its takeover in 2020. An innovative source of financing for this

BiotechFrance

Founded in late 2025, the Avignon biotech signs a scientific collaboration with Gustave Roussy to select its first vaccine candidate in digestive oncology. A funding round has been launched.If cancer vaccines are not new, their effectiveness remains

BiotechFrance

After positive phase 2 results in the post-myocardial infarction setting, CellProthera believes it has now assembled the key clinical, regulatory and industrial building blocks to enter phase 3. The company, positioned at the biotech/medtech interfac

BiotechFrance

Announced in January, the deal became effective at the end of April. The platform designed by PathoQuest is intended to perform viral safety testing and genetic characterization for cell and gene therapies, as well as vaccines. With this French acqui

BiotechFrance

Research to treat this neurodegenerative brain disorder has raised hopes but also many disappointments. Historically focused on dopamine receptors, it is increasingly targeting other mechanisms such as alpha-synuclein accumulation or addressing hered

BiotechFrance

Among the nine start-ups awarded at the HealthTech 2026 Trophies, Biotech Finances highlights three winners that illustrate the diversity of approaches and technological maturities: Methys Dx, FoxBio and One Biosciences.METHYS DX DRIVES CANCER MONITO

BiotechFrance

Second most common chronic neurological disease in France, affecting about 1% of the population, epilepsy remains a conditionthat is little visible to the general public, as well as to investors. The medical director of the specialized investor Angel

BiotechFrance

L’approche innovante de la biotech singapourienne, qui a bénéficié d’un financement de Kurma Partners, est basée sur la mécanobiologie. Nuevocor a le potentiel de transformer le traitement des patients souffrant de cardiomyopathies génétiques dévasta

BiotechFrance

In the wake of the 2025 Nobel Prize in Physiology or Medicine, FoxBio is accelerating the clinical translation of CAR-Tregs to treat severe, disabling chronic inflammatory diseases. A €35M fundraising round is underway. Behind FoxBio, founded on Mar